Clinical trials: Metabolic Diseases
Type 1 Diabetes Mellitus
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex®…
- Trial name
- NCT01526733
- Testing
- Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.
- Trial name
- NCT04288778
- Testing
- Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
- Where
- 10 sites in India
- Volunteers
- 276 people
- Sponsor
- Johnson & Johnson Private Limited
Diabetes Mellitus, Type 1
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a…
- Trial name
- NCT05904743
- Testing
- Afrezza, insulin degludec, Rapid-acting Insulin Analog
- Where
- 19 sites in United States
- Volunteers
- 141 people
- Sponsor
- Mannkind Corporation
Osteopenic Women, Proximal Femur Fracture
Copley II: Long-term Outcome Follow-up Study of Osteoporotic Women Who Underwent a Local Osteo-Enhancement Procedure (LOEP) in the Proximal Femur
To evaluate longer-term (5-7 years) outcomes of the twelve (12) subjects treated with AGN1 Femoral LOEP in the clinical study "A Prospective Pilot Evaluation of Percutaneous Osteo-supplementation in the Proximal Femur of…
- Trial name
- NCT06799143
- Volunteers
- 12 people
- Sponsor
- AgNovos Healthcare, LLC
Obesity, Type 2 Diabetes
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
The trial will enroll healthy volunteers and individuals living with obesity, with and without Type 2 Diabetes. The study, with a treatment period of up to 16 weeks in selected cohorts, will investigate GUB-UCN2 as both a…
- Trial name
- NCT07702890
- Testing
- GUB-UCN2
- Where
- Germany
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Gubra A/S
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
- Trial name
- SYMPHONY-1 (NCT06350890)
- Testing
- HTD1801
- Where
- 56 sites in China
- Volunteers
- 408 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Trial name
- NCT00044408
- Testing
- Ruboxistaurin mesylate
- Where
- 35 sites in United States, Canada and 6 more
- Volunteers
- 200 people
- Sponsor
- Chromaderm, Inc.
Type 1 Diabetes Mellitus
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.
- Trial name
- NCT00939289
- Testing
- Continuous Glucose Monitoring
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- DexCom, Inc.
Hypercholesterolemia
Lipid-lowering Effect of Plant Stanol Drink
To determine the effect of investigational products on serum LDL cholesterol.
- Trial name
- NCT01716390
- Testing
- Drink that contains plant stanols
- Where
- Sweden
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Friedreich Ataxia
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale [mFARS]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
- Trial name
- MOVE-FA (NCT04577352)
- Testing
- Vatiquinone
- Where
- 14 sites in United States, Australia and 7 more
- Volunteers
- 146 people
- Sponsor
- PTC Therapeutics
Osteoporosis
An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass
Osteoporosis affects millions of postmenopausal women in the USA. The current approved treatments are all drugs that prevent bone loss and possibly result in small gains in bone mass.
- Trial name
- NCT00078026
- Testing
- Apomine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Metabolic Syndrome, Anxiety
PRebiotic Intervention for Metabolic and MEntal Health (PRIME)
The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Anxiety, Mood, Stress
- Trial name
- PRIME (NCT06216626)
- Testing
- myota's prebiotic fibre blend
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Myota GmbH
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Type 2 Diabetes Mellitus
Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China
DONATE study is a multi-center, prospective cohort, single arm, observational study to be performed in 3000 Chinese type 2 diabetes mellitus (T2DM) patients recruited from 100 tier 2 or 3 hospitals, China.It is a drug intense…
- Trial name
- DONATE (NCT03156985)
- Where
- 83 sites in China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Dementia
Nutritional Programme for Dementia Elderly Patient
The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.
- Trial name
- NCT00479843
- Testing
- Nutritional programme
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Société des Produits Nestlé (SPN)
Fabry Disease
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
- Trial name
- FLY (NCT06328608)
- Testing
- PRX-102 1 mg/kg every two weeks
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Obesity
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
The study evaluated the safety and efficacy of the vBloc Therapy delivered by the Maestro Rechargeable System compared to a sham control for the treatment obesity.
- Trial name
- ReCharge (NCT01327976)
- Testing
- vBloc (Active Device)
- Where
- 10 sites in United States, Australia
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia
Safety Study of BMS-816336 in Healthy Male Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.
- Trial name
- NCT00979368
- Testing
- BMS-816336
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.